Results 171 to 180 of about 7,362 (230)

UbC4 from Leishmania is a Druggable E2 Ubiquitin Conjugating Enzyme: Structural Basis and Fragment Hits for Future E2-Recruiting PROTAC Development. [PDF]

ACS Omega
Exertier C, Antonelli L, Liuzzi A, Ruffa M, Brufani V, Colotti G, Fiorillo A, Ilari A.   +7 more
europepmc   +1 more source

Targeted Protein Degradation Strategies in DNA Virus Research. [PDF]

Viruses
Lam M, Hill C, Thornburg E, DeSmet M.
europepmc   +1 more source

Targeted degradation of Influenza a virus nucleoprotein via aptamer-based PROTACs for antiviral therapy. [PDF]

Virulence
Li W, Ju Y, Gao Y, Peng J, Qi N.
europepmc   +1 more source

Research Trends and Emerging Frontiers in Proteolysis Targeting Chimeras (PROTACs): A Bibliometric Analysis of 2630 Publications (2001-2025). [PDF]

Pharmaceuticals (Basel)
Su G, Wang Y, Yao L.
europepmc   +1 more source

Optimizing CRBN-ligands for optical targeted protein degradation. [PDF]

RSC Med Chem
Flores JA, DiNardi RG, Burslem GM, Cheng T, Trauner DH.   +4 more
europepmc   +1 more source

Clinical Breakthrough in Targeted Protein Degradation: Reflections on the Approval of ARV-471. [PDF]

Cancer Innov
Rao Y.
europepmc   +1 more source

Research progress and future perspectives in proteolysis-targeting chimeras. [PDF]

Front Pharmacol
Wu N, Xu Z, Dai S, Wang Q.
europepmc   +1 more source

Proteolysis‑targeting chimeras in oral squamous cell carcinoma: Current evidence, translational challenges and future directions (Review). [PDF]

Mol Med Rep
Bai Y, Ma D, Yang X, Wang M.
europepmc   +1 more source

Assays for Measuring the Cell Permeability of Proteolysis-Targeting Chimeras (PROTACs): Performance, Correlations, Applicability and Recommendations. [PDF]

Mol Pharm
Brenner C, Cui Y, Schmidt D, Kirchmair J, Tan L, Braun N.   +5 more
europepmc   +1 more source

Eyes Toward the Clinic: Selective Inhibition and Degradation Approaches to Bromodomain-Containing Proteins. [PDF]

Chembiochem
Scholtz CR, Pomerantz WCK.
europepmc   +1 more source